Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment
Category: #health  By Mateen Dalal  Date: 2019-06-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment

Galactosemia patients are in urgent need of treatment options and the company is committed to advancing AT-007 through clinical development

Reports confirm that Applied Therapeutics Inc. has recently unveiled the initiation of a Phase 1/2 clinical trial of AT-007 in Galactosemia. The study, named ACTION-Galactosemia, will investigate pharmacokinetics and safety of AT-007, which is a central nervous system penetrant Aldose Reductase inhibitor in healthy participants.

The trial will apparently then explore safety, PK and biomarker-based effects in adult subjects with Galactosemia.

Seemingly, Applied Therapeutics is a US-based clinical-stage biopharmaceutical company engaged in developing new drugs against validated molecular targets in indications of huge unmet medical needs.

Sources close to the matter mentioned that the multicenter study will mainly register patients with Classic Galactosemia, the most familiar form of Galactosemia in the US. It will also look to recruit for a single cohort of GALK deficient patients, which is commonly observed in Europe. 

According to Chief Medical Officer of Applied Therapeutics, Riccardo Perfetti, MD, PhD, dietary constraints alone cannot prevent long term complications of disease as the body endogenously creates galactose. Galactosemia patients are in urgent need of treatment options and the company is committed to advancing AT-007 through clinical development as fast as possible owing to this urgent unmet medical requirement. 

Supposedly, Applied Therapeutics is planning to optimize recent FDA guidance that allows biomarker-based development in low prevalence, gradually progressing rare metabolic diseases, like Galactosemia. 

Aldose Reductase is allegedly responsible for creation of a toxic metabolite of galactose, termed galactitol, which has been found to be responsible for several of the long-term complications in Galactosemia.  Initially, patients will be treated with a single dose of AT-007, followed by continuous 27 days of dosing. The clinical trial endpoints will remain tolerability, safety, PK and biomarker-based analyses.

Sources commented that the clinical trial will evidently determine the capability of AT-007 to repress toxic accumulation of galactitol in patients and is looking to explore viability of measuring galactitol levels in the brain through MRI.  

 

Source Credits: https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-initiation-phase-12-study-007

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...